Literature DB >> 20969758

Age- and gender-specific risk of death after first hospitalization for heart failure.

I Vaartjes1, A W Hoes, J B Reitsma, A de Bruin, D E Grobbee, A Mosterd, M I Bots.   

Abstract

BACKGROUND: Hospitalization for heart failure (HF) is associated with high-in-hospital and short- and long-term post discharge mortality. Age and gender are important predictors of mortality in hospitalized HF patients. However, studies assessing short- and long-term risk of death stratified by age and gender are scarce.
METHODS: A nationwide cohort was identified (ICD-9 codes 402, 428) and followed through linkage of national registries. The crude 28-day, 1-year and 5-year mortality was computed by age and gender. Cox regression models were used for each period to study sex differences adjusting for potential confounders (age and comorbidities).
RESULTS: 14,529 men, mean age 74 ± 11 years and 14,524 women, mean age 78 ± 11 years were identified. Mortality risk after admission for HF increased with age and the risk of death was higher among men than women. Hazard ratio's (men versus women and adjusted for age and co-morbidity) were 1.21 (95%CI 1.14 to 1.28), 1.26 (95% CI 1.21 to 1.31), and 1.28 (95%CI 1.24 to 1.31) for 28 days, 1 year and 5 years mortality, respectively.
CONCLUSIONS: This study clearly shows age- and gender differences in short- and long-term risk of death after first hospitalization for HF with men having higher short- and long-term risk of death than women. As our study population includes both men and women from all ages, the estimates we provide maybe a good reflection of 'daily practice' risk of death and therefore be valuable for clinicians and policymakers.

Entities:  

Mesh:

Year:  2010        PMID: 20969758      PMCID: PMC3091563          DOI: 10.1186/1471-2458-10-637

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


Background

Heart failure (HF) is a significant and growing health problem, because of the combination of an ageing population and more effective treatment of its major precursor, myocardial infarction [1]. The prevalence of heart failure, a dominant cause of hospitalization in men and women > 65 years in Western population, is estimated to increase from 0.7% for those 45 to 54 years of age to 8.4% for those aged 75 years or older [2]. Current models that are used for the evaluation of the cost-effectiveness and impact on outcomes of heart failure management programmes or predicting the burden on the health care system use overall mortality risks extracted from studies without detailed information on gender- and age-specific mortality or assumptions concerning death rates are made [3-5]. However, age and gender appear to be important predictors of mortality in hospitalized HF patients [6]. Studies presenting short- and long-term mortality risks stratified by age and gender are scarce. Most available studies present the impact of age and gender on mortality using relative risks or hazard ratios, without providing stratified and detailed mortality risks for age and gender subgroups [6-8]. Some studies reported stratified mortality risks, but these were mostly limited to either age or gender [9-12]. Two studies were identified that reported stratified mortality risks by age and gender [13,14]. However, these studies were restricted to short-term risk of death. Only one study could be identified that presented both short- and long-term risk of death stratified by age and gender [10]. However, this study did not include patients from all ages. Therefore, the purpose of the present study was to estimate detailed short- and long-term mortality risks stratified by age and gender in a large nationwide cohort of patients first hospitalized for HF, including both men and women from all ages.

Methods

For the present study, cohorts were drawn from 1997 and 2000. The choice of these two years was based on pragmatic reasons at the time of the initiation of the project in 2001. The total population of the Netherlands in 1997 and 2000 was 15,567,107 (men 7,696,803, women 7,870,304) and 15,863,950 (men: 7,846,317, women: 8,017, 633), respectively. Approximately 14% of the population was older than 65 years. To construct a cohort of patients admitted for the first time because of HF, information from the national Hospital Discharge Registry (HDR) and the Dutch Population Registry (PR) were linked. Information on cause of death was derived from the Cause of Death Registry of Statistics Netherlands. The registries (which are partly openly available) and linkage procedures have been previously described in detail [15]. In brief, the HDR is a database on admissions, not persons. For each hospital admission a new record is created in the HDR. Following individuals over time based on HDR-information alone is troublesome due to difficulties in identification of different admissions from the same person in time and admissions for the same condition at another hospital (due to referral or to address changes). Yet, linkage (linkage variables date of birth, gender and 4 digits of postal code) with the PR can overcome these issues.

Study population

All hospital admissions for HF (ICD-9-CM code 402, 428) between January 1st and December 31st, 1997 and January 1st and December 31st, 2000, were selected from the HDR (which was previously linked with PR). There were 43,738 hospital admissions. In case of multiple HF admissions for an individual within the same year we only used the first admission, yielding a total of 37,386 heart failure patients. Subsequently, information was collected on hospital admission that may have occurred previously (1995-1997 (data earlier than 1995 were not available since linkage with PR is only possible from 1995 onwards) and 1995-2000, respectively) for the same condition. Those with a previous admission for heart failure were excluded (n = 8,333). This resulted in a cohort consisting of 29,053 patients with a first hospitalization for heart failure in 1997 or 2000 in the Netherlands.

Co-morbidity

The presence of co-morbidity (cardiovascular disease (ICD-9-CM codes 390-459) or diabetes mellitus (ICD-9-CM code 250)) was determined on the basis of the discharge diagnosis of previous hospital admissions or on the basis of a secondary diagnosis at the moment of the index admission. No information on severity of disease, risk factors (hypertension, smoking) or medication use was available in the registry.

Follow-up

Information on mortality of the patients was obtained by linkage of the cohort with national Cause of Death Register. Linkage of the PR (with which the HDR cohort was previously linked) with the Cause of Death Register (Statistics Netherlands) was performed using a unique identification key and therefore was almost complete. Patients were censored if they migrated out of the Netherlands or if their linkage key was not unique anymore during follow-up. Death was coded using the tenth revision of the International Classification of Disease (ICD-10).

Data analysis

We analyzed mortality from all causes by examining the proportion of patients that died within 28-days, 1-year, and 5-years after their first admission for heart failure. Survival time was calculated as the time from the initial admission date in 1997 or 2000 for HF to the date of death from any cause or to the date that a patient was censored, which ever came first. The crude short-term (28 day), 1 year and long-term (5-year) mortality was computed by age and gender according to the actuarial life table method and expressed as percentages. The mortality rate in men was compared to mortality rate in women by calculating relative risks (with 95% CI). Cox regression models were used for each period to study differences between men and women in their risk of death with and without adjusting for potential confounders (age and previous admissions for cardiovascular disease or diabetes mellitus). Data were analyzed with SPSS software, version 14.0 (SPSS Inc, Chicago, Illinois, USA). All analyses were performed in agreement with privacy legislation in the Netherlands [16].

Results

A total of 29,053 patients (mean age 76 ± 11) with a first hospitalization for congestive heart failure in 1997 or 2000 were identified. General characteristics are provided in Table 1. Eighteen, 38% and 67% of all men and 27%, 36% and 66% of all women died within 28 days, 1-year and 5 years, respectively.
Table 1

Characteristics of patients with a hospital admission for heart failure in 1997 or 2000.

MenWomenTotal
Number of patients14,52914,52429,053

Age at admission (years)
  Mean747876
  Standard deviation111111

Prior co-morbidities (%)
cardiovascular disease44.237.540.9
 - ischemic heart disease21.015.018.0
 - acute myocardial infarction9.87.58.6
 - stroke3.23.33.2
 - peripheral arterial disease7.94.66.2
 - other cardiovascular disease24.722.523.6
diabetes mellitus15.120.417.8

Type of hospital (%)
- academic13.09.911.5

Length of stay (days)121312

Origin (%)
-native Dutch908989
Characteristics of patients with a hospital admission for heart failure in 1997 or 2000.

Cause of death

Cardiovascular disease was the most frequent cause of death at 28-days, 1-year and 5-year (table 2). The contribution of cardiovascular diseases as cause of death decreased with increasing follow-up time while the contribution of cancer as a cause of death increased.
Table 2

Causes of death of patients during follow-up after hospital admission for heart failure in the Netherlands.

28 days1-year5-years
Cause of deathMen (n = 2,644)Women (n = 2,661)Men (n = 5,455)Women (n = 5,273)Men (n = 9,677)Women (n = 9,558)

Co-morbidities (%)
Cardiovascular diseases65.270.262.865.959.260.6
 - ischemic heart disease29.924.828.222.326.320.0
  - AMI16.614.914.513.013.111.1
 - congestive heart failure17.021.414.718.012.615.7
 - stroke2.33.23.04.33.75.3
 - peripheral arterial diseases1.91.22.71.93.22.2
 - other cardiovascular diseases14.119.614.119.313.517.7
Cancer7.44.89.86.711.27.5
 - lung cancer2.20.63.30.73.60.8
Diseases of respiratory system14.810.513.19.213.010.0
 - COPD7.34.66.94.36.64.4
Complications from DM2.53.63.24.83.85.5

AMI: acute myocardial infarction, COPD: chronic obstructive respiratory disease, DM: diabetes mellitus

Causes of death of patients during follow-up after hospital admission for heart failure in the Netherlands. AMI: acute myocardial infarction, COPD: chronic obstructive respiratory disease, DM: diabetes mellitus

28 day mortality

Short term mortality risk increased with age in men and women (from 7.5% in men younger than 55 years to 32.9% in men older than 85 years and from 6.9% in women younger than 55 years to 27.2% in women older than 85 years). Higher mortality rates in men compared to women were found across all ages above 65 years (Table 3). Crude overall mortality was similar for men and women (hazard ratio 0.99; 95% CI 0.94 to 1.05). However, after adjustment for potential confounders (age, previous admission for cardiovascular diseases or diabetes mellitus) mortality was higher in men than in women (hazard ratio 1.21; 95% CI 1.14 to 1.28) (Table 4).
Table 3

Mortality risk at 28 days, 1 year and 5 years after first hospital admission (1997 or 2000) for heart failure in the Netherlands, by age and gender.

No. of menNo. of womenAgeMenWomenRR (95% CI) for Men vs Women

No. of DeathsPercentage DeathsNo. of DeathsPercentage Deaths
28-day mortality814525<55617.5366.91.09 (0.73-1.63)
67230355-59477.0165.31.32 (0.76-2.30)
1,11859560-641119.9549.11.09 (0.80-1.49)
1,8511,10765-6919510.511610.51.28 (1.10-1.48)
2,5971,82670-7441916.123112.71.13 (1.01-1.27)
3,0582,83575-7953817.644015.51.29 (1.17-1.41)
2,5793,20880-8466725.964520.11.21 (1.11-1.31)
1,8404,12585+60632.91,12327.21.21 (1.11-1.31)

1-year mortality814525<5514017.27814.91.16 (0.90-1.49)
67230355-5912418.55116.81.10 (0.82-1.48)
1,11859560-6424521.912821.51.02 (0.84-1.23)
1,8511,10765-6950727.424522.11.24 (1.08-1.41)
2,5971,82670-7489234.351828.41.21 (1.11-1.33)
3,0582,83575-791,20539.494033.21.19 (1.11-1.33)
2,5793,20880-841,26449.01,25539.11.25 (1.18-1.33)
1,8404,12585+1,07858.62,05849.91.17 (1.12-1.23)

5-year mortality814525<5527834.214527.61.24 (1.05-1.46)
67230355-5927340.610233.71.21 (1.01-1.45)
1,11859560-6452146.625042.01.11 (0.99-1.24)
1,8511,10765-691,02855.551046.11.21 (1.12-1.30)
2,5971,82670-741,69165.11,00054.81.19 (1.13-1.25)
3,0582,83575-792,19571.81,76562.31.15 (1.11-1.20)
2,5793,20880-842,08981.02,31572.21.12 (1.09-1.15)
1,8404,12585+1,60287.13,47184.11.03 (1.01-1.06)
Table 4

Gender differences in short- and long-term mortality after a first hospital admission (1997 or 2000) for heart failure in the Netherlands

Heart failure

HR (95% CI)*
Crude
28 days0.99 (0.94-1.05)
1 year1.04 (1.00-1.08)
5 years1.03 (1.00-1.06)
Adjusted**
28 days1.21 (1.14-1.28)
1 year1.26 (1.21-1.31)
5 years1.28 (1.24-1.31)

*Hazard ratio (95% Confidence interval) men vs women.

**adjusted for age and prior co-morbidities (previous admissions for cardiovascular disease or diabetes mellitus)

Mortality risk at 28 days, 1 year and 5 years after first hospital admission (1997 or 2000) for heart failure in the Netherlands, by age and gender. Gender differences in short- and long-term mortality after a first hospital admission (1997 or 2000) for heart failure in the Netherlands *Hazard ratio (95% Confidence interval) men vs women. **adjusted for age and prior co-morbidities (previous admissions for cardiovascular disease or diabetes mellitus)

One-year mortality

One-year mortality risk increased with age in men and women (from 17.2% in men younger than 55 years to 58.6% in men older than 85 years and from 14.9% in women younger than 55 years to 49.9% in women older than 85 years). One-year mortality was higher in men than in women across all ages above 65 years (Table 3). The crude overall mortality was similar for men and women at 1 year (hazard ratio 1.04; 95% CI 1.00 to 1.08). However, after adjustment for potential confounders mortality was higher for men compared to women (Table 4).

Five-year mortality

Five-year mortality risk increased with age in men and women (from 34.2% in men younger than 55 years to 87.1% in men older than 85 years and from 27.6% in women younger than 55 years to 84.1% in women older than 85 years). A higher mortality in men compared to women was found across all ages; but this difference was not statistically significant for men and women between 60 and 64 years (Table 3). After adjustment for potential confounders overall five-year mortality was higher for men compared to women (Table 4).

Discussion

The present study using a nationwide cohort of 29,053 patients first hospitalized for heart failure shows clear age- and gender differences in short- and long-term mortality risk. We describe a high mortality over a follow-up of 5 years with men having a higher short- and long-term risk of death than women. Overall mortality risks are presented in several population based cohort studies and in intervention studies evaluating the effect of drug treatment in HF. Similar overall short- and long-term mortality risks were presented in population based cohorts [17,18]. The ARIC study [19] however, reported lower short- and long-term mortality risk. Though patients were considerable younger in the ARIC study (mean age 57 years versus 76 years). Trials [20-23] also report lower mortality risks (1-year mortality risks ranged from 8 to 31% compared to 37%). This likely reflects the younger age and less co-morbidity of patients participating in trials evaluating the effect of drug treatment for HF [24-26]. The limited available age- and gender specific data show that the Swedish short-term mortality risks were lower, the Scottish short- and long-term mortality risks were higher [10], whereas in the United States 30-day mortality risks were lower while 1-year mortality risks were similar [13]. The differences in mortality risk between the countries might reflect differences in health care system and treatment as well as differences in patient characteristics. The latter however remains a matter of speculation since we had no information about the medication prescribed and limited information on clinical characteristics of the patients. The higher mortality risks in men compared to women reported in this study have also been reported in previous large epidemiological studies [27]. A better long-term survival after 10-15 years has been reported in women across all age groups [28]. In contrast to these studies, survival was higher in men than in women in the SOLVD trial [29]. In studies of patients admitted to hospital, women were found to have a lower [13,30] or equal mortality [9]. Possible explanations for the association between gender and mortality risk that have been reported include that men are more likely than women to have an ischemic etiology of their heart failure and that ventricular ejection fraction is higher in female than in male heart failure patients with a nonischemic cause [30]. Our results provide insight in age-and gender-specific risk of death following initial admission for heart failure. As our study population includes both men and women from all ages, the estimates we provide maybe a good reflection of 'daily practice' risk of death and therefore be valuable for clinicians and policymakers. Furthermore, these results can be used for the evaluation of the cost-effectiveness and impact on outcomes of heart failure management programmes that focuses on secondary prevention. The strength of our study is the large size of the cohort obtained from usual care with a large age range and information on both men and women. Even though the validity of national registries has been questioned, several studies have shown that for the Netherlands, the validity is adequate [31]. Positive predictive values for the use of ICD-9 code 428 to identify patients with HF varies between 80.0% [32] and 94.3% [33]. The quality of the applied linkage strategy has been excellent [31]. The cause of death information used in our study was not validated by medical records or autopsy. As a result, the degree of misclassification in the cause of death is unquantifiable. However, as in almost every study using data from vital statistics, some degree of misclassification is inevitable. In addition, the validity of the Dutch national Cause of Death registry has been reported to be higher than the average validity of eight countries in the European Community [34]. To appreciate the findings of this study the following issues needs consideration. The search for previous admissions to maximum of 6 years before, might have led to that some "first" heart failure patients were actually recurrent heart failure patients. The risk of recurrence is the highest within the first two years (44% readmission within 6 months [35] and 70% readmission within 2 years after a first admission for heart failure [36]). The inclusion of recurrent heart failure patients may cause overestimation of absolute mortality rates (as recurrent heart failure patients may be more severe who are likely to have a higher mortality risk) but its extent is difficult to quantify.

Conclusions

In conclusion, this study clearly shows age- and gender differences in short- and long-term risk of death after first hospitalization for heart failure with men having a higher short- and long-term risk of death than women. As our study population includes both men and women from all ages, the estimates we provide maybe a good reflection of 'daily practice' risk of death and therefore be valuable for clinicians and policymakers.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

IV performed the statistical analysis and drafted the manuscript. AH conceived of the study and commented the draft. JR participated in the design of this study and commented the draft. AB participated in the design of this study and commented the draft. DG conceived of the study and commented the draft. AM conceived of the study and commented the draft. MB conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2458/10/637/prepub
  35 in total

1.  [Possibilities for anonymous follow-up studies of patients in Dutch national medical registrations using the Municipal Population Register: a pilot study].

Authors:  J B Reitsma; J W Kardaun; E Gevers; A de Bruin; J van der Wal; G J Bonsel
Journal:  Ned Tijdschr Geneeskd       Date:  2003-11-15

2.  Readmissions and the quality of care in patients hospitalized with heart failure.

Authors:  Jean-Christophe Luthi; Mary Jo Lund; Laura Sampietro-Colom; David G Kleinbaum; David J Ballard; William M McClellan
Journal:  Int J Qual Health Care       Date:  2003-10       Impact factor: 2.038

3.  Certification and coding of two underlying causes of death in The Netherlands and other countries of the European Community.

Authors:  J P Mackenbach; W M Van Duyne; M C Kelson
Journal:  J Epidemiol Community Health       Date:  1987-06       Impact factor: 3.710

4.  Prevalence and mortality rate of congestive heart failure in the United States.

Authors:  D D Schocken; M I Arrieta; P E Leaverton; E A Ross
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

5.  Survival of patients with a new diagnosis of heart failure: a population based study.

Authors:  M R Cowie; D A Wood; A J Coats; S G Thompson; V Suresh; P A Poole-Wilson; G C Sutton
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

6.  Why are patients in clinical trials of heart failure not like those we see in everyday practice?

Authors:  Ffion Lloyd-Williams; Frances Mair; Christopher Shiels; Barbara Hanratty; Pauline Goldstein; Susan Beaton; Simon Capewell; Michael Lye; Ruth Mcdonald; Christopher Roberts; Derek Connelly
Journal:  J Clin Epidemiol       Date:  2003-12       Impact factor: 6.437

7.  Gender differences in advanced heart failure: insights from the BEST study.

Authors:  Jalal K Ghali; Heidi J Krause-Steinrauf; Kirkwood F Adams; Steven S Khan; Yves D Rosenberg; Clyde W Yancy; James B Young; Steven Goldman; Mary Ann Peberdy; JoAnn Lindenfeld
Journal:  J Am Coll Cardiol       Date:  2003-12-17       Impact factor: 24.094

8.  Long-term outcome after a first episode of heart failure. A prospective 7-year study.

Authors:  Christophe Tribouilloy; Otilia Buiciuc; Dan Rusinaru; Dorothée Malaquin; Franck Lévy; Marcel Peltier
Journal:  Int J Cardiol       Date:  2008-12-18       Impact factor: 4.164

9.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000.

Authors:  Maria Schaufelberger; Karl Swedberg; Max Köster; Måns Rosén; Annika Rosengren
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

View more
  10 in total

1.  Gender Differences in Prognostic Markers of All-Cause Death in Patients with Acute Heart Failure: a Prospective 18-Month Follow-Up Study.

Authors:  Xiaoting Wu; Mengli Chen; Kai Wang; Rongrong Gao; Xinli Li
Journal:  J Cardiovasc Transl Res       Date:  2019-05-22       Impact factor: 4.132

2.  The risk of death within 5 years of first hospital admission in older adults.

Authors:  Kieran L Quinn; Nathan M Stall; Zhan Yao; Therese A Stukel; Peter Cram; Allan S Detsky; Chaim M Bell
Journal:  CMAJ       Date:  2019-12-16       Impact factor: 8.262

3.  Sex Differences in the Mortality Risk of Elderly Patients with Systolic Heart Failure in Taiwan.

Authors:  Tsung-Jui Wu; Gen-Min Lin; Chin-Sheng Lin; Pang-Yen Liu; Kuan-Jen Su; Chia-Chang Lin; Tzu-Chiao Lin; Shu-Meng Cheng; Shih-Hua Lin; Eiki Takimoto; Issei Komuro; Wei-Shiang Lin
Journal:  Acta Cardiol Sin       Date:  2020-11       Impact factor: 2.672

4.  The Dutch hospital standardised mortality ratio (HSMR) method and cardiac surgery: benchmarking in a national cohort using hospital administration data versus a clinical database.

Authors:  S Siregar; M E Pouw; K G M Moons; M I M Versteegh; M L Bots; Y van der Graaf; C J Kalkman; L A van Herwerden; R H H Groenwold
Journal:  Heart       Date:  2013-12-13       Impact factor: 5.994

5.  Prognosis of patients with dementia: results from a prospective nationwide registry linkage study in the Netherlands.

Authors:  Irene E van de Vorst; Ilonca Vaartjes; Mirjam I Geerlings; Michael L Bots; Huiberdina L Koek
Journal:  BMJ Open       Date:  2015-10-28       Impact factor: 2.692

Review 6.  Mortality in heart failure patients.

Authors:  Ibadete Bytyçi; Gani Bajraktari
Journal:  Anatol J Cardiol       Date:  2014-08-19       Impact factor: 1.596

7.  Risk factors for sudden cardiac death to determine high risk patients in specific patient populations that may benefit from a wearable defibrillator.

Authors:  Hilal Mohammed Khan; Stephen J Leslie
Journal:  World J Cardiol       Date:  2019-03-26

8.  Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men.

Authors:  J Buddeke; G B Valstar; I van Dis; F L J Visseren; F H Rutten; H M den Ruijter; I Vaartjes; M L Bots
Journal:  BMC Public Health       Date:  2020-01-10       Impact factor: 3.295

9.  Trends for Readmission and Mortality After Heart Failure Hospitalisation in Malaysia, 2007 to 2016.

Authors:  Yvonne Mei Fong Lim; Su Miin Ong; Stefan Koudstaal; Wen Yea Hwong; Houng Bang Liew; Jeyamalar Rajadurai; Diederick E Grobbee; Folkert W Asselbergs; Sheamini Sivasampu; Ilonca Vaartjes
Journal:  Glob Heart       Date:  2022-03-08

10.  Baseline conditions and nutritional state upon hospitalization are the greatest risks for mortality for cardiovascular diseases and for several classes of diseases: a retrospective study.

Authors:  Lara Loreggian; Elena Tagliabue; Filippo Giorgini; Ahmed S Zakaria; Marco Fanchini; Annamaria Veronelli; Antonio E Pontiroli
Journal:  Sci Rep       Date:  2022-06-25       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.